Zobrazeno 1 - 7
of 7
pro vyhledávání: '"L K, Pearson"'
Publikováno v:
Geochemistry: Exploration, Environment, Analysis. 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb73f2276e6630073fa5cc8802a1f8b
https://doi.org/10.1144/geochem2021-056
https://doi.org/10.1144/geochem2021-056
Autor:
C. Collatos, L. K. Pearson
Publikováno v:
Equine Veterinary Journal. 45:261-264
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73282ded305f3c24fc5f0a2e43d4f547
https://doi.org/10.1111/evj.12067
https://doi.org/10.1111/evj.12067
Autor:
J G, Slatter, L J, Schaaf, J P, Sams, K L, Feenstra, M G, Johnson, P A, Bombardt, K S, Cathcart, M T, Verburg, L K, Pearson, L D, Compton, L L, Miller, D S, Baker, C V, Pesheck, R S, Lord
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 28(4)
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100 microCi) [(14)C]CPT-11 in eight patients with solid tumors. Mean +/- S.D. recovery of radioactivity in urine and feces was 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a052ff69246a2104d461df4a37672029
https://pubmed.ncbi.nlm.nih.gov/10725311
https://pubmed.ncbi.nlm.nih.gov/10725311
Autor:
J C, Fleishaker, L K, Pearson, D W, Knuth, B, Gomez-Mancilla, S F, Francom, M J, McIntosh, S, Freestone, N E, Azie
Publikováno v:
International journal of clinical pharmacology and therapeutics. 37(10)
The objectives of this study were to characterize the safety, tolerability and pharmacokinetics of a single, oral dose of PNU-142633F escalating over the range of 1.0 mg to 100 mg (free base equivalents).This was a randomized, double-blind, single-do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::812117c0f56c6a636e53c715e8dbfc49
https://pubmed.ncbi.nlm.nih.gov/10543315
https://pubmed.ncbi.nlm.nih.gov/10543315
Publikováno v:
Biopharmaceuticsdrug disposition. 19(2)
Tirilazad is a membrane lipid peroxidation inhibitor being studied for the management of subarachnoid hemorrhage; phenytoin is used for seizure prophylaxis in the same disorder. The induction of tirilazad clearance by phenytoin was assessed in 12 vol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f64c1993d8da5a9f3aeaccd6189fd121
https://pubmed.ncbi.nlm.nih.gov/9533108
https://pubmed.ncbi.nlm.nih.gov/9533108
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 277(2)
The effect of ketoconazole, a CYP3A inhibitor, on the oral bioavailability of tirilazad mesylate was assessed in 12 healthy subjects, who received the following treatments in a crossover design: a) 10 mg/kg tirilazad mesylate solution orally on the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b6449af6cd5d76f263aee938e7949687
https://pubmed.ncbi.nlm.nih.gov/8627582
https://pubmed.ncbi.nlm.nih.gov/8627582